pralsetinib
Sign in to saveAlso known as BLU-667, BLU667, trans-pralsetinib
Pralsetinib, sold under the brand name Gavreto, is a medication approved for RET mutation-positive medullary thyroid cancer (MTC) and RET fusion-positive differentiated thyroid cancer (DTC) refractory to radioactive iodine (RAI) therapy. Pralsetinib is a tyrosine kinase inhibitor. It is taken by mouth.
Wikidata facts
- Subclass of
- chemical compound
- Mass
- 533.2662994840001
- Has use
- medication
Show 4 more facts
- isomeric SMILES
- COC1(C(=O)N[C@@H](C)c2ccc(-n3cc(F)cn3)nc2)CCC(c2nc(C)cc(=Nc3cc(C)[nH]n3)[nH]2)CC1
- chemical formula
- C₂₇H₃₂FN₉O₂
- canonical SMILES
- COC1(C(O)=NC(C)c2ccc(-n3cc(F)cn3)nc2)CCC(c2nc(C)cc(=Nc3cc(C)[nH]n3)[nH]2)CC1
- subject has role
- protein kinase inhibitors
via Wikidata · CC0
~3 min read
Encyclopedic overview
6 sectionsContents
- Medical uses
- History
- Society and culture
- Legal status
- References
- External links
Pralsetinib, sold under the brand name Gavreto, is a medication approved for RET mutation-positive medullary thyroid cancer (MTC) and RET fusion-positive differentiated thyroid cancer (DTC) refractory to radioactive iodine (RAI) therapy. Pralsetinib is a tyrosine kinase inhibitor. It is taken by mouth.
The most common adverse reactions include increased aspartate aminotransferase (AST), decreased hemoglobin, decreased lymphocytes, decreased neutrophils, increased alanine aminotransferase (ALT), increased creatinine, increased alkaline phosphatase, fatigue, constipation, musculoskeletal pain, decreased calcium, hypertension, decreased sodium, decreased phosphate, and decreased platelets.
Excerpted from Wikipedia’s “pralsetinib” article, available under the CC BY-SA 4.0 licence.